Abstract
Brazil has experienced some of the highest numbers of COVID-19 cases and deaths globally and from May 2021 made Latin America a pandemic epicenter. Although SARS-CoV-2 established sustained transmission in Brazil early in the pandemic, important gaps remain in our understanding of virus transmission dynamics at the national scale. Here, we describe the genomic epidemiology of SARS-CoV-2 using near-full genomes sampled from 27 Brazilian states and a bordering country - Paraguay. We show that the early stage of the pandemic in Brazil was characterised by the co-circulation of multiple viral lineages, linked to multiple importations predominantly from Europe, and subsequently characterized by large local transmission clusters. As the epidemic progressed under an absence of effective restriction measures, there was a local emergence and onward international spread of Variants of Concern (VOC) and Variants Under Monitoring (VUM), including Gamma (P.1) and Zeta (P.2). In addition, we provide a preliminary genomic overview of the epidemic in Paraguay, showing evidence of importation from Brazil. These data reinforce the usefulness and need for the implementation of widespread genomic surveillance in South America as a toolkit for pandemic monitoring that provides a means to follow the real-time spread of emerging SARS-CoV-2 variants with possible implications for public health and immunization strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was financed by Sao Paulo Research Foundation (FAPESP) (Grants Number: 2020/10127-1 and 2020/05367-3, 2013/08135-2), the Central Public Health Laboratories, Blood Center of Ribeirao Preto and supported by the Brazilian Ministry of Health and the Pan American Health Organization PAHO/WHO (APO21-00010098). This work was supported in part through National Institutes of Health USA grant U01 AI151698 for the United World Arbovirus Research Network (UWARN), the CRP- ICGEB RESEARCH GRANT 2020 Project CRP/BRA20-03, Contract CRP/20/03, the Oswaldo Cruz Foundation VPGDI-027-FIO-20-2-2-30, the Brazilian Ministry of Health (SCON2021-00180), the CNPq (426559/2018-5) and the Faperj E-26/202.930/2016. MG and LCJA are supported by Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) (E-26/202.248/2018(238504); E26/202.665/2019(247400)). JX is supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) - Finance Code 001. JL is supported by a lectureship by the Department of Zoology of the University of Oxford. VF is supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) (88882.349290/2019-01) and a Flagship grant from the South African Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI). ECH is funded by an ARC Australian Laureate Fellowship (FL170100022). MLN is supported by FAPESP (Grant 20/04836-0) and partially supported by a NIH grant to CreateNeo (U01AI151807).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was approved by the Ethics Review Committee of the Pan American Health Organization (PAHOERC.0344.01), the Federal University of Minas Gerais (CEP/CAAE:32912820.6.1001.5149), the University of Sao Paulo (CEP/FZEA: 4.780.992) and the Blood Center of Ribeirao Preto (CEP/HCRP-FMRP: 50367721.7.1001.5440)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos